|
Oct. 1, 2025
| This week’s commercialization news and insights for biopharma leaders
The funding lapse triggered by the U.S. government shutdown is the latest test for an agency that’s already dealt with significant layoffs and leadership upheaval this year.
|
A pact to offer “most favored nation” prices to state Medicaid programs and via direct-to-consumer channels doesn’t affect those on commercial insurance or who won’t pay out of pocket.
|
Carve-outs for generics, European exports and companies onshoring drug production will likely shield most branded drugs from the 100% levies Trump announced Thursday.
|
Discover how biopharma leaders are adapting to the new tools and technologies poised to tweak the RNA drugmaking recipe amid threats to funding and contracts in the biotech sector in this
|
The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable type of hormone therapy.
|
News roundup
George Tidmarsh criticized Aurinia’s lupus drug in a later-retracted social media post. Elsewhere, the FDA approved a new Novartis drug and two biotechs cut staff.
|
From Our Library
Webinar - on demand
Custom content for Endava
|
Infographic
Custom content for Woven Health Collective
|
Playbook
Custom content for Evaluate
|
View all resources
What We're Reading
The Washington Post
|
BioSpace
|
| 
